Get the Stockscreener App
14.97
1.56%
0.23
After Hours:
14.70
-0.27
-1.80%
Gyre Therapeutics Inc stock is traded at $14.97, with a volume of 27,142.
It is up +1.56% in the last 24 hours and up +11.14% over the past month.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
See More
Previous Close:
$14.74
Open:
$14.62
24h Volume:
27,142
Relative Volume:
0.55
Market Cap:
$1.40B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+11.14%
6M Performance:
-1.12%
1Y Performance:
+0.00%
1-Day Range:
$14.53
$14.97
1-Week Range:
$14.28
$15.09
52-Week Range:
$8.26
$27.10
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Name
Gyre Therapeutics Inc
Sector
Industry
Phone
(619) 949-3681
Address
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
View All
Gyre Therapeutics Inc Stock (GYRE) Latest News
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis - The Manila Times
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 3.8%What's Next? - MarketBeat
AQR Capital Management LLC Invests $778,000 in Mativ Holdings, Inc. (NYSE:MATV) - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap UpStill a Buy? - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Shares Down 6.2% - Defense World
Coronation Fund Managers Ltd. Buys 1,044 Shares of The Sherwin-Williams Company (NYSE:SHW) - Defense World
Eaton Vance California Municipal Income Trust (NYSE:CEV) Major Shareholder Sells $282,451.70 in Stock - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Trading 3.3% HigherHere's What Happened - MarketBeat
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference - The Manila Times
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Down 7.0% in August - MarketBeat
Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday - Benzinga
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 4.9% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Trading Up 6.6% - MarketBeat
Gyre Therapeutics Inc (GYRE) Stock Price & Chart | Trade Now - Capital.com
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
Gyre Therapeutics (NASDAQ:GYRE) Shares Down 8.9% - MarketBeat
Short Interest in Gyre Therapeutics, Inc. (NASDAQ:GYRE) Grows By 5.4% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Trading 4.1% Higher - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Shares Down 6.6% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Sees Unusually-High Trading Volume - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Stock Quotes, Forecast and News Summary - Benzinga
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Sees Significant Growth in Short Interest - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 8.2% - MarketBeat
Vanguard Group Inc. Reduces Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up to $10.40 - MarketBeat
GYRE Stock Earnings: Gyre Therapeutics Reported Results for Q2 2024 - InvestorPlace
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 3.9% - MarketBeat
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update - BioSpace
Gyre Therapeutics (NASDAQ:GYRE) Trading 6.7% Higher - MarketBeat
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference - ForexTV.com
Gyre Therapeutics Welcomes Dr. Epstein to Leadership Team - TipRanks
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors - StockTitan
Gyre Therapeutics (NASDAQ:GYRE) versus Insmed (NASDAQ:INSM) Critical Comparison - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 8.4% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 18.9% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 8.4% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Trading Up 4.9% - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Up 67.9% in July - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Shares Down 4.3% - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 4.3% - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Update - Defense World
Supply@ME Capital (LON:SYME) Stock Price Up 16.7% - Defense World
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Update - Defense World
Head to Head Comparison: Puma Biotechnology (NASDAQ:PBYI) versus Gyre Therapeutics (NASDAQ:GYRE) - Defense World
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Up 15.1% in June - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 5.5% - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 4.3% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Shares Up 3.7% - Defense World
Gyre Therapeutics faces Nasdaq delisting over audit rule - Investing.com India
Gyre Therapeutics faces Nasdaq delisting over audit rule By Investing.com - Investing.com
Gyre Therapeutics Seeks Compliance Amid Board Reshuffle - TipRanks
Gyre Therapeutics Inc Stock (GYRE) Financials Data
There is no financial data for Gyre Therapeutics Inc (GYRE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Gyre Therapeutics Inc Stock (GYRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| USMAN NASSIM | Director |
Jun 28 '24 |
Sale |
12.00 |
3,452 |
41,438 |
1,636 |
| USMAN NASSIM | Director |
May 01 '24 |
Option Exercise |
6.93 |
20,000 |
138,600 |
21,636 |
| USMAN NASSIM | Director |
May 01 '24 |
Sale |
14.13 |
20,000 |
282,577 |
1,636 |
| USMAN NASSIM | Director |
Apr 01 '24 |
Option Exercise |
6.93 |
20,000 |
138,600 |
21,636 |
| USMAN NASSIM | Director |
Apr 01 '24 |
Sale |
16.15 |
20,000 |
323,000 |
1,636 |
| USMAN NASSIM | Director |
Mar 15 '24 |
Option Exercise |
6.93 |
20,000 |
138,600 |
21,636 |
| USMAN NASSIM | Director |
Mar 15 '24 |
Sale |
17.26 |
20,000 |
345,200 |
1,636 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):